ACW's Principal Activity is the development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases.
Last (Price) | |
Change | 0.00 (0.00) |
Bid / Ask | - |
Volume | |
Volume (4w avg) | |
Turnover | |
Open | |
Day Range | - |
VWAP | |
Prev Close | |
Last Trade |
1 Week | |
1 Month | |
2022 YTD | |
1 Year | |
vs Sector (1yr) | -20.25% |
vs ASX 200 (1yr) | -27.49% |
Date | Heading | Pages | File Size | Time |
---|---|---|---|---|
Actinogen Medical Limited (ACW, formerly Actinogen Limited) is an ASX-listed biotechnology company developing innovative treatments for Alzheimer's disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. It focusses on the development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases within Australia.
Incorporated Actinogen Limited was incorporated on 26/03/1999 in Western Australia.
Head Office | Sydney NSW 2000 |
Website | www.actinogen.com.au |
Registry | Automic Group |
Auditor | Ernst & Young |
Date Listed | 16 Oct 2007 |
Date | Event |
---|---|
29/08/2022 | Report (Prelim) |
29/08/2022 | Report (Annual) |
07/10/2022 | Report (Annual) |
23/02/2023 | Report (Interim) |
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
ACW directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
The current holdings of ACW directors.
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
Name | Last Notice | Total Shares | Shares Held (%) |
---|---|---|---|
BVF Partners L.P | 24/08/2021 | 239,927,273 | 14.88 |
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
Date | Close | Change | %Chg | Open | High | Low | Volume | Turnover |
---|---|---|---|---|---|---|---|---|
Year | Closing Price | Last Trade |
---|---|---|
2021 | $0.125 | 30 June |
2020 | $0.022 | 30 June |
2019 | $0.01 | 28 June |
2018 | $0.048 | 29 June |
2017 | $0.061 | 28 June |
2016 | $0.072 | 28 June |
2015 | $0.072 | 30 June |
2014 | $0.011 | 30 June |
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.